Hidehito Horinouchi summarizes some abstracts of WCLC24 part 2

Hidehito Horinouchi shared on X:

“Trailblazing Targets: New Insights

Chairs: Drs. Jacob Sands and Lorenza Landi.

HRQoL Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12

The New Generation of Cytotoxics

Chairs: Dr. Kirsty Wai-Chung Lee, Aakash Desai, Jhanelle Gray
Sacituzumab Govitecan + Pembrolizumab + Carboplatin in 1L Metastatic NSCLC: The EVOKE-02 Study

Novel Immunotherapy Strategies and Combinations

Chairs: Cheryl Ho, Anil Tibdewal

Speaker: Thomas Wu

SAFFRON-301: Tislelizumab + Sitravatinib in NSCLC Progressing on/after Chemo and Anti-PD-(L)1

Local Consolidative Therapy for Metastatic NSCLC

Chairs: Drs. John Cho and Delphine Antoni

Speaker: Dr. Shuanghu Yuan

Radiotherapy Combined with Enhanced Immunotherapy for NSCLC.”

Hidehito Horinouchi is the Assistant Chief of the National Cancer Center Hospital. He also serves as the Secretary General of the Lung Cancer Study Group, Japan Clinical Oncology Group, and the Deputy Chief of the Center for Education and Professional Career Development at the National Cancer Center Hospital. He specializes in multimodal treatment strategies, including medical, surgical, and radiation oncology, for patients with thoracic malignancies.